Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

OnCore Login
Login to Oncore Network

Login to Oncore Network

Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

Robert H. Lurie Comprehensive Cancer Center of Northwestern University

676 North St. Clair Street, 21st Floor, Chicago, IL 60611 - USA
Maggie Daley Center for Women’s Cancer Care, Prentice Women's Hospital
250 E Superior, 4th Floor, Chicago, IL 60611 - USA

First established at Northwestern University in 1974, the center was dedicated as the Robert H. Lurie Cancer Center of Northwestern University in 1991 through a gift of endowment from Ann and Robert H. Lurie. The center’s title was modified in 1997, when the National Cancer Institute (NCI) awarded the Lurie Cancer Center the “comprehensive” designation, reflecting the center’s dedication to the highest standards of cancer research, patient care, education, and community outreach.

Today, the Lurie Cancer Center is one of only 41 NCI-designated “comprehensive” cancer centers in the nation. In addition, the Lurie Cancer Center is a founding member of the National Comprehensive Cancer Network (NCCN), an alliance of 25 of the world’s leading cancer centers dedicated to improving the quality and effectiveness of care provided to patients with cancer. It also is part of the Big Ten Cancer Research Consortium, a network of academic institutions working together on highly translational clinical trials using the expertise of Big Ten universities.

The Lurie Cancer Center is affiliated with four teaching hospitals in Chicago — Northwestern Memorial Hospital, Ann & Robert H. Lurie Children’s Hospital of Chicago, the Rehabilitation Institute of Chicago, and the Jesse Brown Veteran’s Affairs Medical Center – treating more than 10,000 new cancer cases each year.

Website: Robert H. Lurie Comprehensive Cancer Center

Contact:
Cary Passaglia, CCRP
312-695-1378

Trials at this location:

HCRN GU16-260

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Status: Closed to Accrual
Read More

HCRN LUN18-335

An Open-Label Randomized Phase II Study of Combining Osimertinib with and without Ramucirumab in TKI-naïve EGFR-mutant Locally Advanced or Metastatic NSCLC

Status: Open to Accrual
Read More

HCRN BRE12-158

A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients with Triple Negative Breast Cancer.

Status: Closed to Accrual
Read More

HCRN MEL17-309

Phase II single-arm multi-center study of adjuvant ipilimumab in combination with nivolumab in subjects with high-risk ocular melanoma

Status: Closed to Accrual
Read More